Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Is CJC-1295 Legal in Florida? How to Access It Legally

By
Published Updated Last reviewed
12 linked public sourcesEditorial, sourcing, and corrections policy

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

Key numbers

  • 5.8 to 8.1 daysEstimated half-life after one injection in healthy adults (Teichman trials)Source: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07
  • 0 yes and 13 noFDA advisory committee vote on CJC-1295 free base: 0 yes and 13 no, against adding itSource: fda.gov, as cited 2026-11-07
  • 63%Headache in Teichman trial subjects given the drug, versus 14% on placeboSource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07
  • 7.5-foldTrough growth hormone a week after one injection in healthy men aged 20 to 40Source: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07

At a glance

  • FDA approval / None. FDA found no approved product containing any form of CJC-1295 in the 12 countries it searched, and none authorized by the European Medicines Agency [1]
  • State pharmacy bulk list / In none of the three categories (page updated May 14, 2026) [2]
  • Outsourcing facility list / Not listed (updated March 21, 2025) [3]
  • Advisory committee vote / December 4, 2024: 0 yes, 13 no on the free base; 1 yes, 12 no on the acetate; 0 yes, 13 no on each DAC form [4]
  • HHS peptide policy / The October 2026 draft names six other peptides, not CJC-1295 [5]
  • Human data / Three published studies, all of the DAC form, all in healthy volunteers [1]
  • Sport / WADA prohibits it at all times, in and out of competition [6]
  • Products sold online / Mostly labeled research use only, which are not FDA-approved drugs [1]

Is CJC-1295 approved for any use?

No. It is an investigational long-acting analogue of growth hormone-releasing hormone, developed by ConjuChem Biotechnologies of Montreal and first described in 2005 [1][7]. FDA searched Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Norway, Spain and the United Kingdom and found no approved product containing any form of CJC-1295 [1]. Only three human studies have been published, all of the DAC form, all in healthy volunteers, and FDA found no study of any form in people with a disease [1].

What do FDA's compounding lists say?

FDA's list of bulk substances for state-licensed pharmacies and physicians (updated May 14, 2026) puts CJC-1295 in none of its three categories, and FDA's list for outsourcing facilities (updated March 21, 2025) does not include it [2][3]. It is not a component of an FDA-approved drug and has no USP monograph, so FDA's category 1 policy, under which the agency generally takes no action against compounders that meet its conditions, does not cover it [2][3].

It once sat in category 2, the substances FDA says may present significant safety risks, and moved to the nominated-but-withdrawn table after the nominators withdrew. FDA's concerns remain posted, including 'serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction' [8]. On December 4, 2024 FDA's Pharmacy Compounding Advisory Committee voted 0 yes and 13 no on CJC-1295 free base, 1 yes and 12 no on the acetate, and 0 yes and 13 no on each of the three DAC forms [4]. HHS's October 2026 draft enforcement-discretion policy names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500, not CJC-1295 [5].

Questions worth asking

Choose the questions you want to keep

What did the human studies show?

Teichman and colleagues ran two randomized, placebo-controlled, double-blind ascending-dose trials of 28 and 49 days in healthy adults aged 21 to 61 [9]. After one injection the estimated half-life was 5.8 to 8.1 days, mean growth hormone rose 2- to 10-fold for six days or more, and mean IGF-I rose 1.5- to 3-fold for 9 to 11 days [9]. Ionescu and Frohman gave healthy men aged 20 to 40 one injection of 60 or 90 micrograms/kg; a week later GH pulses were unchanged in frequency and size while trough GH was 7.5-fold higher [10].

In the Teichman trials, injection-site reactions occurred in about 70% of treated subjects in the first study and in all treated subjects in the second, and headache in 63% versus 14% on placebo [1][9]. No serious adverse reactions were reported in those trials [9]. In 2006 ConjuChem withdrew CJC-1295 DAC from clinical trials after a participant in a phase 2 trial in HIV lipodystrophy (192 enrolled) died. FDA cites news reports that the person had chest discomfort after an 11th weekly dose and that the most likely explanation was undiagnosed coronary artery disease. The data were never published, so a link to the drug is neither shown nor excluded [1].

Adam Nessim, MD on why the CJC peptide and ipamorelin may suit active older adults

Dr Adam Nessim describes CJC as a synthetic analog of growth hormone releasing hormone that prompts the pituitary to produce the body's own growth hormone rather than adding it directly. He notes that it is often combined with ipamorelin, which he calls a selective growth hormone secretagogue with minimal effect on cortisol or prolactin. In his view, it is a practical option for people in their forties or beyond whose recovery feels slower or who struggle to hold on to muscle despite training well. He stresses that the goal is supporting the body's own output and that it still needs monitoring from a physician who knows the space. He also says human data is limited, though phase one and two trials were conducted with acceptable safety.

Who is speaking?

Adam Nessim, MD. Physician, as the channel name states (MD) Background

Episode notes and full video

What about products sold online as research chemicals?

FDA noted that CJC-1295 products sold online are mostly labeled research use only, including blends with ipamorelin and GHRPs [1]. Research-use-only products are not FDA-approved drugs [1].

Is it banned in sport?

WADA's 2026 Prohibited List names CJC-1295, and CJC-1293, in S2.2.4 as growth hormone-releasing hormone analogues, prohibited at all times in and out of competition, and S2 substances are non-Specified Substances [6]. It is also named in the 2027 List, in force January 1, 2027 [11].

Frequently asked questions

Is CJC-1295 legal in Florida?
FDA's records show no approved product and no listed compounding route for CJC-1295 [1][2][3]. They do not address Florida's own pharmacy rules, so they cannot establish that obtaining it in Florida is legal.
Can a pharmacy compound CJC-1295 on a prescription?
A prescription does not create an approved product. CJC-1295 has no USP monograph and is not a component of an approved drug, so FDA's category 1 policy does not apply to it [2][3].
Does the October 2026 HHS peptide policy cover CJC-1295?
No. That draft enforcement-discretion policy names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 only [5].
What did the advisory committee vote on CJC-1295?
On December 4, 2024 FDA's Pharmacy Compounding Advisory Committee voted against adding every form: 0 yes and 13 no on the free base, 1 yes and 12 no on the acetate, and 0 yes and 13 no on each DAC form. FDA reviewers had proposed that no form be added to the pharmacy bulks list [4].
Is CJC-1295 banned in sports?
WADA names it in S2.2.4 as a growth hormone-releasing hormone analogue and prohibits it at all times, in and out of competition, on both the 2026 and 2027 Prohibited Lists [6][11].

What people actually ask

Can you order peptides in Florida?

FDA's records show no approved product and no listed compounding route for CJC-1295, and they do not address Florida's own pharmacy rules. So these federal records cannot show whether ordering it in Florida is allowed. The question is not established by the federal records alone.

Where can I get a CJC peptide?

There is no FDA-approved or FDA-listed source for CJC-1295 in the US. Products sold online are mostly labeled research use only, and research-use-only products are not FDA-approved drugs.

Is CJC-1295 legal in the United States?

It is not approved for any use in the United States. It is an investigational drug, and it appears in none of the three state-licensed pharmacy categories or on the outsourcing-facility list. Those records do not establish that obtaining it is legal.

References

  1. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  2. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  3. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  4. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  5. Official web page. Official web page
  6. World Anti-Doping Agency. World Anti-Doping Agency
  7. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
  8. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
  9. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
  10. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
  11. World Anti-Doping Agency. World Anti-Doping Agency
  12. Adam Nessim, MD. 14 Peptides Could Soon Be Legal Again. I Explain Them All. Accessed 2026-11-11.
Evidence overview for Is CJC-1295 Legal in Florida? How to Access It Legally